Regeneron Investor Interest

News

Regeneron Just Bought Your DNA From 23andMe

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from customers using ancestry testing and other services.

The Times of India on MSN · 1d

Bankrupt DNA testing company 23andMe to be acquired by Regeneron for $256 million

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand and a significant data br

The Economic Times on MSN · 2d

Regeneron to rescue 23andMe from bankruptcy in $256 million deal — but who really owns your genetic data now and what happens to your DNA privacy?

Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and what happens to millions of users' sensitive information. Once worth $6 billion,

14h

23andMe sale reveals what your genetic data is worth. It’s less than you think

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Rolling Out2d

The fall of 23andMe and what it means for your DNA

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

2don MSN

Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...

Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

TechCrunch2d

Pharma giant Regeneron to buy 23andMe and its customers’ data for $256M

Pharmaceutical maker Regeneron announced Monday it will buy ... s stock price also plummeted to near-zero amid waning consumer interest in the company’s DNA testing kits. 23andMe’s founder ...

STAT5d

Amgen loses $400 million antitrust battle to Regeneron

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

5don MSN

Regeneron wins over $400M jury award as Amgen found liable in antitrust case

Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...

Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 2.39% to $584.99 Thursday, on what proved to be an all-around positive ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results